Tarceva and Ketoprofen drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tarceva (erlotinib hydrochloride) and Ketoprofen (ketoprofen). Common drug interactions include acne among females and decreased appetite among males.

The phase IV clinical study analyzes what interactions people have when they take Tarceva and Ketoprofen. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Tarceva?

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in lung cancer. eHealthMe is studying from 31,036 Tarceva users. Check the latest studies of Tarceva.

What is Ketoprofen?

Ketoprofen has active ingredients of ketoprofen. It is often used in pain. eHealthMe is studying from 15,048 Ketoprofen users. Check the latest studies of Ketoprofen.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 02, 2026

14 people who take Tarceva and Ketoprofen together, and have interactions are studied.

Tarceva and Ketoprofen drug interactions.

What are the common drug interactions of Tarceva and Ketoprofen, by gender? *:

female:

  1. Acne (skin problems that cause pimples)
  2. Androgenetic alopecia (common form of hair loss)
  3. Diarrhoea
  4. Xerosis (abnormal dryness of the skin or mucus membranes)
  5. Death
  6. Pulmonary oedema (fluid accumulation in the lungs)
  7. Decreased appetite
  8. Dry skin
  9. Gastric perforation (hole in stomach)
  10. General physical health deterioration (weak health status)

male:

  1. Decreased appetite
  2. Diarrhoea
  3. Dizziness
  4. Meningitis (inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges)
  5. Pyrexia (fever)
  6. Vomiting
  7. Intervertebral disc protrusion (spinal disc protrusion)
  8. Nerve root compression
  9. Skin haemorrhage (bleeding into skin)
  10. Surgery

What are the common drug interactions of Tarceva and Ketoprofen, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Abdominal distension
  2. Abdominal pain
  3. Abdominal pain upper
  4. Anxiety
  5. Back injury
  6. Chills (felling of cold)
  7. Contusion (a type of hematoma of tissue in which capillaries)
  8. Death
  9. Decreased appetite
  10. Diarrhoea

40-49:

n/a

50-59:

  1. Gastric perforation (hole in stomach)

60+:

  1. Diarrhoea
  2. Decreased appetite
  3. Disease progression
  4. General physical health deterioration (weak health status)
  5. Meningitis (inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges)
  6. Pyrexia (fever)
  7. Xerosis (abnormal dryness of the skin or mucus membranes)
  8. Back injury
  9. Intervertebral disc protrusion (spinal disc protrusion)
  10. Nerve root compression

What are the existing conditions these people have? *

  1. Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 14.29%
  2. Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 2 people, 14.29%
  3. Large Cell Carcinoma Of The Respiratory Tract Stage Unspecified (lung cancer of large cells unspecified): 2 people, 14.29%
  4. Pancreatic Carcinoma (pancreatic cancer): 1 person, 7.14%
  5. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 7.14%
  6. Metastatic Bronchial Carcinoma (spread of cancer to bronchi tumour): 1 person, 7.14%
  7. Metastases To Central Nervous System (cancer spreads to central nervous system): 1 person, 7.14%
  8. Lung Cancer - Non-Small Cell (lung cancer): 1 person, 7.14%
  9. Bronchial Carcinoma (lung cancer): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Tarceva and Ketoprofen?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Tarceva and Ketoprofen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tarceva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ketoprofen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tarceva and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ketoprofen and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on erlotinib hydrochloride and ketoprofen (the active ingredients of Tarceva and Ketoprofen, respectively), and Tarceva and Ketoprofen (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: